- Home
- DRTS vs ZURA Comparison
DRTS vs ZURA Comparison
Compare DRTS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRTS | ZURA |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.2M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DRTS | ZURA |
|---|---|---|
| Price | $3.90 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $9.00 | ★ $11.38 |
| AVG Volume (30 Days) | 62.0K | ★ 405.4K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.97 |
| 52 Week High | $4.69 | $4.68 |
Technical Indicators
Market Signals| Indicator | DRTS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 50.59 |
| Support Level | $3.67 | $3.51 |
| Resistance Level | $4.28 | $3.84 |
| Average True Range (ATR) | 0.25 | 0.23 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 55.29 | 36.15 |
Price Performance
Historical ComparisonAbout DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.